Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04053673
Title RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Ribon Therapeutics, Inc.
Indications

lymphoma

Advanced Solid Tumor

Therapies

RBN-2397

Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.